Doctor OctoPlus
This article was originally published in The Gray Sheet
Executive Summary
SurModics obtains an option to acquire an exclusive license from OctoPlus for the OctoDEX and PolyActive biodegradable drug delivery polymers. SurModics plans to use the technology, which is suitable for use with proteins and large molecule therapeutic agents, as biodegradable coatings or as fully degradable products. PolyActive is used for controlled release of proteins and hydrophobic small molecule drugs. OctoDEX is based on "cross-linked dextran microspheres" used for timed release of proteins and large particles, such as liposomes and antigens. Both polymers are undergoing preclinical and clinical evaluation for use as pharmaceutical formulations...
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.